Switch theme
Sign up to access all valuation multiples
Aarti Pharmalabs Ltd manufactures pharmaceuticals and nutraceuticals with a footprint. It manufactures Active Pharmaceutical Ingredients (API), pharmaceutical intermediates, and xanthine derivatives in India. It also offers Contract Development and Manufacturing Services (CDMS) for drug substance (NCE, RSM, Intermediates) projects. Geographically, the company generates maximum revenue from its customers located outside India.
2019
2.1K+
Last FY Revenue $248M
Last FY EBITDA $55.6M
$1.0B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Aarti Pharmalabs achieved revenue of $248M and an EBITDA of $55.6M.
Aarti Pharmalabs expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Aarti Pharmalabs valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $248M | XXX | XXX | XXX |
| Gross Profit | XXX | $116M | XXX | XXX | XXX |
| Gross Margin | XXX | 47% | XXX | XXX | XXX |
| EBITDA | XXX | $55.6M | XXX | XXX | XXX |
| EBITDA Margin | XXX | 22% | XXX | XXX | XXX |
| EBIT | XXX | $44.2M | XXX | XXX | XXX |
| EBIT Margin | XXX | 18% | XXX | XXX | XXX |
| Net Profit | XXX | $31.9M | XXX | XXX | XXX |
| Net Margin | XXX | 13% | XXX | XXX | XXX |
| Net Debt | XXX | $45.6M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Aarti Pharmalabs's stock price is INR 910 (or $11).
Aarti Pharmalabs has current market cap of INR 82.5B (or $966M), and EV of INR 86.0B (or $1.0B).
See Aarti Pharmalabs trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.0B | $966M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Aarti Pharmalabs has market cap of $966M and EV of $1.0B.
Aarti Pharmalabs's trades at 4.2x EV/Revenue multiple, and 19.0x EV/EBITDA.
Equity research analysts estimate Aarti Pharmalabs's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Aarti Pharmalabs's P/E ratio is not available.
See valuation multiples for Aarti Pharmalabs and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $966M | XXX | $966M | XXX | XXX | XXX |
| EV (current) | $1.0B | XXX | $1.0B | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 4.2x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | 19.0x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | 23.8x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | 31.9x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -107.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialAarti Pharmalabs's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $34K for the same period.
Aarti Pharmalabs's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Aarti Pharmalabs's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Aarti Pharmalabs and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | 22% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $34K | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 29% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Jubilant Pharmova | XXX | XXX | XXX | XXX | XXX | XXX |
| Biocon | XXX | XXX | XXX | XXX | XXX | XXX |
| Syngene International | XXX | XXX | XXX | XXX | XXX | XXX |
| Dishman Carbogen Amics | XXX | XXX | XXX | XXX | XXX | XXX |
| Cohance Lifesciences | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Aarti Pharmalabs acquired XXX companies to date.
Last acquisition by Aarti Pharmalabs was XXXXXXXX, XXXXX XXXXX XXXXXX . Aarti Pharmalabs acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Aarti Pharmalabs founded? | Aarti Pharmalabs was founded in 2019. |
| Where is Aarti Pharmalabs headquartered? | Aarti Pharmalabs is headquartered in India. |
| How many employees does Aarti Pharmalabs have? | As of today, Aarti Pharmalabs has 2.1K+ employees. |
| Is Aarti Pharmalabs publicy listed? | Yes, Aarti Pharmalabs is a public company listed on BOM. |
| What is the stock symbol of Aarti Pharmalabs? | Aarti Pharmalabs trades under 543748 ticker. |
| When did Aarti Pharmalabs go public? | Aarti Pharmalabs went public in 2023. |
| Who are competitors of Aarti Pharmalabs? | Similar companies to Aarti Pharmalabs include e.g. Jubilant Pharmova, Biocon, Syngene International, Dishman Carbogen Amics. |
| What is the current market cap of Aarti Pharmalabs? | Aarti Pharmalabs's current market cap is $966M |
| Is Aarti Pharmalabs profitable? | Yes, Aarti Pharmalabs is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
